No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the Hypertension in the Very Elderly Trial
(HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over.
The Hypertension in the Very Elderly Trial
(HYVET), which enrolled participants 80 years of age and older, demonstrated that reducing systolic BP (SBP) from 170 mm Hg to 145 mm Hg with indapamide sustained release 1.
Treating hypertensive patients 80 and older could help lower their risk of cognitive decline, according to the results of an analysis of the Hypertension in the Very Elderly Trial
(HYVET), published in the July 8 issue of The Lancet Neurology.